Holen Sie sich die Stockscreener-App
2.535
5.76%
-0.155
Schlusskurs vom Vortag:
$2.69
Offen:
$2.71
24-Stunden-Volumen:
162.49K
Relative Volume:
3.05
Marktkapitalisierung:
$75.26M
Einnahmen:
$6.21M
Nettoeinkommen (Verlust:
$-19.92M
KGV:
-2.4143
EPS:
-1.05
Netto-Cashflow:
$-16.76M
1W Leistung:
-7.48%
1M Leistung:
-21.27%
6M Leistung:
-4.34%
1J Leistung:
+7.11%
1-Tages-Spanne:
$2.50
$2.71
1-Wochen-Bereich:
$2.50
$2.78
52-Wochen-Spanne:
$1.81
$3.798
InspireMD Inc. Stock (NSPR) Company Profile
Firmenname
InspireMD Inc.
Sektor
Branche
Telefon
972 3 6917691
Adresse
4 Menorat Hamaor Street, Tel Aviv
Vergleichen Sie NSPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
2.535 | 75.26M | 6.21M | -19.92M | -16.76M | -1.05 |
|
ABT
Abbott Laboratories
|
131.69 | 228.39B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
101.24 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
373.30 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.49 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.87 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2016-01-07 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-03-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2013-11-26 | Eingeleitet | Oppenheimer | Outperform |
InspireMD Inc. Aktie (NSPR) Neueste Nachrichten
InspireMD Inc Files For Mixed Shelf Of Up To $200 MillionSEC Filing - MarketScreener
InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com - Defense World
InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Reviewing Anika Therapeutics (NASDAQ:ANIK) and InspireMD (NYSE:NSPR) - Defense World
InspireMD, Inc. (NSPR) Reports Q4 Loss, Tops Revenue Estimates - MSN
InspireMD, Inc. (NASDAQ:NSPR) Q4 2024 Earnings Call Transcript - Insider Monkey
InspireMD Inc (NSPR) Q4 2024 Earnings Call Highlights: Revenue Growth Amid Rising Expenses and ... By GuruFocus - Investing.com Canada
InspireMD Inc. Reports 2024 Financial Results and Strategic Progress - TipRanks
InspireMD’s Earnings Call: Cautious Optimism Amid Challenges - TipRanks
InspireMD earnings beat by $0.01, revenue topped estimates - Investing.com Canada
Earnings call transcript: InspireMD Q4 2024 beats revenue forecast, stock rises - Investing.com India
InspireMD Inc reports results for the quarter ended December 31Earnings Summary - TradingView
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
InspireMD reports Q4 EPS (19c) vs (16c) last year - TipRanks
INSPIREMD Earnings Results: $NSPR Reports Quarterly Earnings - Nasdaq
InspireMD Achieves Record $1.95M Revenue as FDA Approval Nears - StockTitan
InspireMD, Inc. SEC 10-K Report - TradingView
InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com - Defense World
InspireMD (NYSE:NSPR) and Bluejay Diagnostics (NASDAQ:BJDX) Head to Head Survey - Defense World
InspireMD (NYSE:NSPR) Now Covered by StockNews.com - Defense World
InspireMD, Inc. to Host Earnings Call - ACCESS Newswire
InspireMD announces inducement grants under Nasdaq listing rule - MSN
InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
When Will InspireMD Release Its 2024 Results? Key Date for Carotid Stent Maker Announced - StockTitan
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Is InspireMD's Hiring Spree a Signal for Investors? Company Awards 138K Shares to New Talent - StockTitan
Investors in InspireMD (NASDAQ:NSPR) have unfortunately lost 78% over the last five years - Yahoo Finance
NSPR stock touches 52-week high at $3.43 amid robust growth - Investing.com
InspireMD and NAMSA to begin study of carotid stent system for TCAR procedures - Yahoo
InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal - GlobeNewswire
InspireMD And NAMSA To Partner On CGuardians II Pivotal Clinical Trial Of The CGuard Prime 80 Cm Carotid Stent System For Use In TCAR Procedures - Marketscreener.com
Major Clinical Trial Alert: InspireMD's Revolutionary TCAR Stent Targets $1B+ Market - StockTitan
StockNews.com Begins Coverage on InspireMD (NYSE:NSPR) - Defense World
Investors in InspireMD (NASDAQ:NSPR) from five years ago are still down 86%, even after 10% gain this past week - Simply Wall St
Compliance Issues And Stock Developments Hit Nasdaq Companies - Evrim Ağacı
InspireMD Awards Strategic Employee Stock Grants to Accelerate Growth, Adds 9 New Hires - StockTitan
StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR) - Defense World
InspireMD : Breakthrough device in clinical trials aims to prevent strokes -January 20, 2025 at 07:59 am EST - Marketscreener.com
Here's Why We're Watching InspireMD's (NASDAQ:NSPR) Cash Burn Situation - Yahoo Finance
InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com - MarketBeat
Finanzdaten der InspireMD Inc.-Aktie (NSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):